Cochrane Review Group
Gynaecological, Neuro-oncology and Orphan Cancer
129 systematic reviews in Gynaecological, Neuro-oncology and Orphan Cancer ask 1,590 questions. 17.7% have no studies to answer them, 25.8% rest on very low certainty evidence and 25.5% reach moderate or high certainty.
Reviews
129
Questions
1,590
current versions
No studies
17.7%
Moderate or high
25.5%
No studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings 2: PLD alone vs other conventional chemotherapy Quality of life · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 2: PLD alone vs other conventional chemotherapy Overall severe adverse events (grade > 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 2 studies · 964 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Anaemia (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 5 studies · 1968 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 6 studies · 2184 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 3 studies · 1222 participants | Very low |
Summary of findings 3: PLD with chemotherapy vs PLD alone Quality of life · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 4.01 [1, 16.01] | 2 studies · 1028 participants | Very low |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 0.38 [0.2, 0.74] | 4 studies · 1900 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Progression‐free survival (PFS) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | HR 0.94 [0.85, 1.04] | 4 studies · 1803 participants | Very low |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Quality of life (QoL) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Hypertension grade ≥ 3 · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Reviews 129
Interventions to improve psychosocial well‐being in female BRCA‐mutation carriers following risk‐reducing surgery
CochraneSoF table
14 questions
Long‐term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma
CochraneSoF table
8 questions
Interval brain imaging for adults with cerebral glioma
CochraneSoF table
5 questions
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males
CochraneSoF table
30 questions
Communication skills training for healthcare professionals working with people who have cancer
CochraneSoF table
7 questions
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
CochraneSoF table
24 questions
Non‐steroidal anti‐inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia
CochraneSoF table
3 questions
Hyperbaric oxygenation for tumour sensitisation to radiotherapy
CochraneSoF table
18 questions
Selenium for preventing cancer
CochraneSoF table
15 questions
Anticoagulation for people with cancer and central venous catheters
CochraneSoF table
24 questions
Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer
CochraneSoF table
30 questions
Laparoscopy versus laparotomy for the management of early stage endometrial cancer
CochraneSoF table
3 questions
Antigen‐specific active immunotherapy for ovarian cancer
CochraneSoF table
7 questions
Epidermal growth factor receptor blockers for the treatment of ovarian cancer
CochraneSoF table
20 questions
Anti‐angiogenic therapy for high‐grade glioma
CochraneSoF table
8 questions
Hormone replacement therapy for women previously treated for endometrial cancer
CochraneSoF table
5 questions
Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with cancer
CochraneSoF table
31 questions
Influenza vaccines in immunosuppressed adults with cancer
CochraneSoF table
4 questions
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
CochraneSoF table
30 questions
Anticoagulation for perioperative thromboprophylaxis in people with cancer
CochraneSoF table
20 questions
Interventions for promoting habitual exercise in people living with and beyond cancer
CochraneSoF table
7 questions
Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer
CochraneSoF table
28 questions
Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults
CochraneSoF table
6 questions
Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer
CochraneSoF table
4 questions
Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery
CochraneSoF table
13 questions